Curaxins: Anticancer Compounds That Simultaneously Suppress NF-κB and Activate p53 by Targeting FACT-Reference-Cited by-同舟云学术

Curaxins: Anticancer Compounds That Simultaneously Suppress NF-κB and Activate p53 by Targeting FACT

Published:2011-08-10 Issue:95 Volume:3 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Gasparian Alexander V.¹,Burkhart Catherine A.¹,Purmal Andrei A.¹,Brodsky Leonid¹,Pal Mahadeb²,Saranadasa Madhi²,Bosykh Dmitry A.¹,Commane Mairead²,Guryanova Olga A.³,Pal Srabani²,Safina Alfiya²,Sviridov Sergey⁴,Koman Igor E.²,Veith Jean²,Komar Anton A.⁵,Gudkov Andrei V.¹²,Gurova Katerina V.¹²

Affiliation:

1. Cleveland BioLabs Inc., Buffalo, NY 14203, USA.

2. Department of Cell Stress Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.

3. Department of Molecular Genetics, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

4. ChemBridge Corp., San Diego, CA 92121, USA.

5. Center for Gene Regulation in Health and Disease, Department of Biology, Cleveland State University, Cleveland, OH 44105, USA.

Abstract

The quinacrine-related compounds curaxins target multiple procancer pathways through FACT complex.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference56 articles.

1. New molecular targets in radiotherapy: DNA damage signalling and repair in targeted and non-targeted cells

2. Impaired DNA damage response — An Achilles' heel sensitizing cancer to chemotherapy and radiotherapy

3. New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents

4. Amplification of Anticancer Drug-Induced DNA Damage and Apoptosis by DNA-Binding Compounds

5. Inflammation and p53: A Tale of Two Stresses

Cited by 210 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MiR-204/-211 double knockout exacerbates rheumatoid arthritis progression by promoting splenic inflammation;International Immunopharmacology;2024-10

2. FACT inhibitor CBL0137, administered in an optimized schedule, potentiates radiation therapy for glioblastoma by suppressing DNA damage repair;Journal of Neuro-Oncology;2024-09-09

3. FACT inhibitor CBL0137, administered in an optimized schedule, potentiates radiation therapy for glioblastoma by suppressing DNA damage repair;2024-09-09

4. Image-Based Quantitative Single-Cell Method Showed Increase of Global Chromatin Accessibility in Tumor Compared to Normal Cells;2024-09-06

5. Activation and Evasion of the FEAR Pathway by RNA Viruses;2024-08-22